Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTUD7B | Q6GQQ9 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29561629 | 0.76 | OTUD7B (1.00) | OTUD7B | |
| SCHEMBL20608038 | 0.76 | OTUD7B (1.00) | OTUD7B | |
| SCHEMBL20732518 | 0.75 | OTUD7B (0.60) | OTUD7B | |
| SCHEMBL20608085 | 0.74 | OTUD7B (1.00) | OTUD7B | |
| SCHEMBL20721831 | 0.74 | OTUD7B (1.00) | OTUD7B | |
| SCHEMBL29561853 | 0.72 | OTUD7B (0.57) | OTUD7B | |
| SCHEMBL20608095 | 0.72 | OTUD7B (0.56) | OTUD7B | |
| SCHEMBL17037682 | 0.72 | OTUD7B (0.56) | OTUD7B | |
| SCHEMBL20608098 | 0.71 | OTUD7B (0.55) | OTUD7B | |
| SCHEMBL20721771 | 0.70 | OTUD7B (1.00) | OTUD7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3423454-B1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-05-25 | — | — | EP | claimed |
| US-20220106315-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-04-07 | — | — | US | claimed |
| CN-108602823-B | Spiro-condensed pyrrolidine derivatives as Deubiquitinase (DUB) inhibitors | 特殊治疗有限公司 | 2022-04-01 | — | — | CN | claimed |
| US-10654853-B2 | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2020-05-19 | — | — | US | claimed |
| US-20190048008-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2019-02-14 | — | — | US | claimed |
| EP-4067355-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYME (DUB) INHIBITORS | Mission Therapeutics Limited (GB) | 2022-10-05 | — | — | EP | disclosed |
| EP-4067355-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYME (DUB) INHIBITORS | Mission Therapeutics Limited (GB) | 2022-10-05 | — | — | EP | disclosed |
| EP-3423454-B1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-05-25 | — | — | EP | disclosed |
| EP-3423454-B1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-05-25 | — | — | EP | disclosed |
| US-20220106315-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-04-07 | — | — | US | disclosed |
| US-20220106315-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-04-07 | — | — | US | disclosed |
| CN-108602823-B | Spiro-condensed pyrrolidine derivatives as Deubiquitinase (DUB) inhibitors | 特殊治疗有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-11236092-B2 | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
| US-11236092-B2 | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
| US-20200247803-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2020-08-06 | — | — | US | disclosed |
| US-20200247803-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2020-08-06 | — | — | US | disclosed |
| US-10654853-B2 | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| US-10654853-B2 | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| US-20190048008-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2019-02-14 | — | — | US | disclosed |
| US-20190048008-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106315-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | OTUB1, UBE2E1, RCE1 | OTUD7B 25/4885 |
| US-20200247803-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | OTUB1, UBE2E1, RCE1 | OTUD7B 25/4885 |
| US-10654853-B2 | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors | OTUB1, UBE2E1, RCE1 | OTUD7B 25/4885 |
| US-20190048008-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | OTUB1, UBE2E1, RCE1 | OTUD7B 25/4885 |
| US-11236092-B2 | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors | OTUB1, UBE2E1, RCE1 | OTUD7B 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.